Supplementary Table 1: Distribution of chemotherapy regimens utilized in resected and non- resected LAPC patients.
Variable
All patients (n=415)
Resecte d (n=84)
Non- resected (n=331) Neoadjuvant chemotherapy regimen, n (%)
Gemcitabine/nab-paclitaxel Gemcitabine/capecitabine
FOLFIRINOX and Gemcitabine/nab-paclitaxel Modified FOLFIRINOX
FOLFIRINOX Gemcitabine 5-FU/Capecitabine
FOLFIRINOX/Capecitabine
87 (23%) 11 (3%) 72 (19%)
28 (7%) 156 (41%)
19 (5%) 3 (1%) 2 (1%)
16 (19%) - 14 (17%)
7 (8%) 44 (52%)
1 (1%) 1 (1%) 1 (1%)
71 (22%) 11 (3%) 58 (18%)
21 (6%) 112 (34%)
18 (5%) 2 (1%) 1 (0.3%) Adjuvant chemotherapy regimen, n (%)
Gemcitabine/nab-paclitaxel Gemcitabine/capecitabine
FOLFIRINOX and Gemcitabine/nab-paclitaxel Modified FOLFIRINOX
FOLFIRINOX Gemcitabine Capecitabine FOLFIRI
FOLFIRINOX/Capecitabine
5 (1%) 2 (0.4%) 2 (0.4%) 2 (0.4%) 11 (3%)
8 (2%) 1 (0.2%)
6 (2%) 1 (0.2%)
5 (6%) 2 (2%) 2 (2%) 2 (2%) 11 (13%)
8 (10%) 1 (1%) 6 (7%) 1 (1%)
N/A N/A N/A N/A N/A N/A N/A N/A N/A
